The polyvalent streptococcus pneumoniae active immunizing agent is a vaccine that mainly prevents pneumonia caused by Streptococcus pneumoniae. It contains a variety of serotypes that often cause streptococcus pneumoniae infection. After vaccination, it can effectively reduce the risk of pneumonia infection.
The global market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent include GlaxoSmithKline, LG Chem, Merck, Panacea Biotec, AstraZeneca, Pfizer, Shire, Pnuvax Incorporated and Serum Institute, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by region & country, by Type, and by Application.
The Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polyvalent Streptococcus Pneumoniae Active Immunizing Agent.
Market Segmentation
By Company
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
Segment by Type:
9-Valent
13-Valent
23-Valent
Others
Segment by Application
Hospital
Community Clinics
Public Health Agencies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Introduction
1.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Size Forecast
1.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value (2019-2030)
1.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume (2019-2030)
1.2.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Price (2019-2030)
1.3 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Trends & Drivers
1.3.1 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Industry Trends
1.3.2 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Drivers & Opportunity
1.3.3 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Challenges
1.3.4 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Players Revenue Ranking (2023)
2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Company (2019-2024)
2.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Players Sales Volume Ranking (2023)
2.4 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Company Players (2019-2024)
2.5 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Average Price by Company (2019-2024)
2.6 Key Manufacturers Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent
2.9 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Competitive Analysis
2.9.1 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polyvalent Streptococcus Pneumoniae Active Immunizing Agent as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 9-Valent
3.1.2 13-Valent
3.1.3 23-Valent
3.1.4 Others
3.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type
3.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, by Type (2019-2030)
3.2.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, by Type (%) (2019-2030)
3.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Type
3.3.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume, by Type (2019-2030)
3.3.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume, by Type (%) (2019-2030)
3.4 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Community Clinics
4.1.3 Public Health Agencies
4.1.4 Others
4.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application
4.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, by Application (2019-2030)
4.2.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, by Application (%) (2019-2030)
4.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Application
4.3.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume, by Application (2019-2030)
4.3.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume, by Application (%) (2019-2030)
4.4 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Region
5.1.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Region (2019-2024)
5.1.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Region (2025-2030)
5.1.4 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Region (%), (2019-2030)
5.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Region
5.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Region (2019-2024)
5.2.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Region (2025-2030)
5.2.4 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume by Region (%), (2019-2030)
5.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
5.4.2 North America Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
5.5.2 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
5.6.2 Asia Pacific Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
5.7.2 South America Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
5.8.2 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value
6.2.1 Key Countries/Regions Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.2.2 Key Countries/Regions Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.3.2 United States Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.4.2 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.5.2 China Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.5.3 China Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.6.2 Japan Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.7.2 South Korea Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.8.2 Southeast Asia Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value, 2019-2030
6.9.2 India Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Type (%), 2023 VS 2030
6.9.3 India Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Information
7.1.2 GlaxoSmithKline Introduction and Business Overview
7.1.3 GlaxoSmithKline Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.1.4 GlaxoSmithKline Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.1.5 GlaxoSmithKline Recent Development
7.2 LG Chem
7.2.1 LG Chem Company Information
7.2.2 LG Chem Introduction and Business Overview
7.2.3 LG Chem Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.2.4 LG Chem Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.2.5 LG Chem Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.3.5 Merck Recent Development
7.4 Panacea Biotec
7.4.1 Panacea Biotec Company Information
7.4.2 Panacea Biotec Introduction and Business Overview
7.4.3 Panacea Biotec Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Panacea Biotec Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.4.5 Panacea Biotec Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Company Information
7.5.2 AstraZeneca Introduction and Business Overview
7.5.3 AstraZeneca Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.5.4 AstraZeneca Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.5.5 AstraZeneca Recent Development
7.6 Pfizer
7.6.1 Pfizer Company Information
7.6.2 Pfizer Introduction and Business Overview
7.6.3 Pfizer Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Pfizer Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.6.5 Pfizer Recent Development
7.7 Shire
7.7.1 Shire Company Information
7.7.2 Shire Introduction and Business Overview
7.7.3 Shire Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Shire Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.7.5 Shire Recent Development
7.8 Pnuvax Incorporated
7.8.1 Pnuvax Incorporated Company Information
7.8.2 Pnuvax Incorporated Introduction and Business Overview
7.8.3 Pnuvax Incorporated Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Pnuvax Incorporated Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.8.5 Pnuvax Incorporated Recent Development
7.9 Serum Institute
7.9.1 Serum Institute Company Information
7.9.2 Serum Institute Introduction and Business Overview
7.9.3 Serum Institute Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Serum Institute Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.9.5 Serum Institute Recent Development
7.10 Shinogi
7.10.1 Shinogi Company Information
7.10.2 Shinogi Introduction and Business Overview
7.10.3 Shinogi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Shinogi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.10.5 Shinogi Recent Development
7.11 Shenzhen Kangtai Biological Products
7.11.1 Shenzhen Kangtai Biological Products Company Information
7.11.2 Shenzhen Kangtai Biological Products Introduction and Business Overview
7.11.3 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.11.5 Shenzhen Kangtai Biological Products Recent Development
7.12 SK Bioscience
7.12.1 SK Bioscience Company Information
7.12.2 SK Bioscience Introduction and Business Overview
7.12.3 SK Bioscience Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.12.4 SK Bioscience Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.12.5 SK Bioscience Recent Development
7.13 Walvax Biotechnology
7.13.1 Walvax Biotechnology Company Information
7.13.2 Walvax Biotechnology Introduction and Business Overview
7.13.3 Walvax Biotechnology Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Walvax Biotechnology Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.13.5 Walvax Biotechnology Recent Development
7.14 Eli Lilly
7.14.1 Eli Lilly Company Information
7.14.2 Eli Lilly Introduction and Business Overview
7.14.3 Eli Lilly Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Eli Lilly Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.14.5 Eli Lilly Recent Development
7.15 Abera
7.15.1 Abera Company Information
7.15.2 Abera Introduction and Business Overview
7.15.3 Abera Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Abera Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.15.5 Abera Recent Development
7.16 Sanofi
7.16.1 Sanofi Company Information
7.16.2 Sanofi Introduction and Business Overview
7.16.3 Sanofi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Sanofi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.16.5 Sanofi Recent Development
7.17 Genentech
7.17.1 Genentech Company Information
7.17.2 Genentech Introduction and Business Overview
7.17.3 Genentech Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Genentech Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Offerings
7.17.5 Genentech Recent Development
8 Industry Chain Analysis
8.1 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Industrial Chain
8.2 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Model
8.5.2 Sales Channel
8.5.3 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
听
听
*If Applicable.